Microsatellite Stable (MSS) is an inclusion criterion in 65 clinical trials for colorectal carcinoma, of which 50 are open and 15 are closed. Of the trials that contain Microsatellite Stable (MSS) and colorectal carcinoma as inclusion criteria, 26 are phase 1 (20 open), 18 are phase 1/phase 2 (17 open), and 21 are phase 2 (13 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 30 clinical trials for malignant solid tumor, of which 26 are open and 4 are closed. Of the trials that contain Microsatellite Stable (MSS) and malignant solid tumor as inclusion criteria, 13 are phase 1 (10 open), 13 are phase 1/phase 2 (12 open), and 4 are phase 2 (4 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 28 clinical trials for colorectal adenocarcinoma, of which 23 are open and 5 are closed. Of the trials that contain Microsatellite Stable (MSS) and colorectal adenocarcinoma as inclusion criteria, 4 are phase 1 (3 open), 7 are phase 1/phase 2 (6 open), 16 are phase 2 (13 open), and 1 is phase 3 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 18 clinical trials for non-small cell lung carcinoma, of which 16 are open and 2 are closed. Of the trials that contain Microsatellite Stable (MSS) and non-small cell lung carcinoma as inclusion criteria, 7 are phase 1 (7 open), 8 are phase 1/phase 2 (7 open), and 3 are phase 2 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 12 clinical trials for breast carcinoma, of which 10 are open and 2 are closed. Of the trials that contain Microsatellite Stable (MSS) and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open), 5 are phase 1/phase 2 (5 open), and 3 are phase 2 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 10 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 10 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 8 are phase 1/phase 2 (8 open) and 2 are phase 2 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 8 clinical trials for endometrial carcinoma, of which 8 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and endometrial carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 8 clinical trials for gastric adenocarcinoma, of which 8 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and gastric adenocarcinoma as inclusion criteria, 6 are phase 1/phase 2 (6 open) and 2 are phase 2 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 8 clinical trials for pancreatic carcinoma, of which 8 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and pancreatic carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 7 clinical trials for head and neck squamous cell carcinoma, of which 7 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and head and neck squamous cell carcinoma as inclusion criteria, 5 are phase 1 (5 open) and 2 are phase 1/phase 2 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 5 clinical trials for melanoma, of which 5 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and melanoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain Microsatellite Stable (MSS) and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 5 clinical trials for rectal adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain Microsatellite Stable (MSS) and rectal adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 5 clinical trials for urothelial carcinoma, of which 4 are open and 1 is closed. Of the trials that contain Microsatellite Stable (MSS) and urothelial carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 4 clinical trials for esophageal adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and esophageal adenocarcinoma as inclusion criteria, 3 are phase 1/phase 2 (3 open) and 1 is phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 4 clinical trials for gastric carcinoma, of which 4 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and gastric carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 4 clinical trials for renal cell carcinoma, of which 3 are open and 1 is closed. Of the trials that contain Microsatellite Stable (MSS) and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 3 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 3 clinical trials for esophageal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 3 clinical trials for pancreatic ductal adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and pancreatic ductal adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 3 clinical trials for prostate carcinoma, of which 3 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 3 clinical trials for small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and bladder urothelial carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 2 clinical trials for cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 2 clinical trials for colon adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain Microsatellite Stable (MSS) and colon adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and fallopian tube carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and hepatocellular carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 2 clinical trials for nasopharyngeal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 2 clinical trials for ovarian endometrioid adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 2 clinical trials for primary peritoneal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain Microsatellite Stable (MSS) and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for alveolar soft part sarcoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and alveolar soft part sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for anal canal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for appendix mucinous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains Microsatellite Stable (MSS) and appendix mucinous adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and bladder carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and breast adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and chordoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for colon carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and colon carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for colorectal mucinous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains Microsatellite Stable (MSS) and colorectal mucinous adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and cutaneous melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for digestive system carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and digestive system carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for esophagogastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and esophagogastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for fallopian tube clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and fallopian tube clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for fallopian tube endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and neuroendocrine tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and oropharyngeal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for primary peritoneal clear cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and primary peritoneal clear cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for primary peritoneal endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for prostate adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains Microsatellite Stable (MSS) and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for small intestinal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and small intestinal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for uterine corpus endometrial stromal sarcoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and uterine corpus endometrial stromal sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Microsatellite Stable (MSS) is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains Microsatellite Stable (MSS) and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].